Innovative management techniques for Alzheimer's disease

Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management

Not applicable Interventional Shaanxi Hospital of Traditional Chinese Medicine · NCT05641480

This study is testing a new way to manage Alzheimer's disease by combining traditional Chinese medicine with modern treatments like music therapy and medications to see if it helps patients feel better.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment150 (estimated)
Ages55 Years to 75 Years
SexAll
SponsorShaanxi Hospital of Traditional Chinese Medicine Academic / other
Locations2 sites (Xi'an, Shaanxi and 1 other locations)
Trial IDNCT05641480 on ClinicalTrials.gov

What this trial studies

This project focuses on managing Alzheimer's disease through a combination of traditional Chinese medicine and modern therapeutic approaches. Participants are categorized into groups based on their cognitive decline and receive interventions such as transcutaneous electrical acupoint stimulation and music therapy, along with medications like donepezil. The treatment spans 24 weeks, with evaluations conducted at multiple intervals to assess efficacy and caregiver burden. The aim is to develop a comprehensive treatment plan tailored to individual needs based on traditional Chinese medicine principles.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 55-75 with subjective cognitive decline, mild cognitive impairment, or mild dementia.

Not a fit: Patients with moderate or severe dementia or those with significant comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could enhance the quality of life for patients with Alzheimer's disease and related cognitive impairments.

How similar studies have performed: While there is ongoing research in cognitive therapies, this specific combination of traditional Chinese medicine and modern techniques is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Meeting the diagnostic criteria of SCD, MCI and mild dementia;
* Memory decline (self-reported or confirmed by both informants);
* Age 55-75 years;
* Memory impairment has not reached the diagnostic criteria of moderate and severe dementia;
* Hachinski ischemia scale score ≤ 4;
* Exclude any other systemic diseases that can cause brain dysfunction;
* Hamilton Depression Scale \< 17;
* The subject or guardian signed the informed consent.

Exclusion Criteria:

* There are advanced, serious or unstable other diseases, such as liver, kidney and other serious primary diseases;
* Severe hearing and visual impairment, can not cooperate with the assessment;
* with active epilepsy;
* Previous history of mental illness;
* Moderate or severe dementia, cerebral infarction or any physical or mental disorder that may lead to brain dysfunction;
* Having used other drugs that may cause cognitive function changes or heart, brain, kidney and other important organs failure before inclusion;
* Under 55 years old or above 75 years old;
* Unable to cooperate with the completion of the corresponding assessment and inspection and quit;
* Those who are likely to have poor compliance with the test;
* Participants in other subjects.

Where this trial is running

Xi'an, Shaanxi and 1 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Alzheimer DiseaseSubjective Cognitive DeclineMild Cognitive ImpairmentMild DementiaAlzheimer's Disease
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.